Associations between the 17q21 region and allergic rhinitis in 5 birth cohorts - 05/02/15
The BAMSE study was supported by the Swedish Research Council, the Swedish Heart–Lung Foundation, Stiftelsen Frimurare Barnhuset i Stockholm, Matsumura's donation, the Stockholm County Council, the Swedish Environmental Protection Agency, the Swedish Society for Medical Research, and the Swedish Foundation for Strategic Research. The PIAMA study is supported by The Netherlands Organization for Health Research and Development, The Netherlands Organization for Scientific Research, The Netherlands Asthma Fund, The Netherlands Ministry of Spatial Planning, Housing, and the Environment, and The Netherlands Ministry of Health, Welfare and Sport. Part of the genotyping of PIAMA was supported by BBMRI-NL (grant no. CP2010-29) and the GABRIEL study (FP6 grant, European Commission, 018996). The GINIplus study was supported for the first 3 years by the Federal Ministry for Education, Science, Research and Technology (intervention arm) and Helmholtz Zentrum Munich (former Gesellschaft für Strahlenforschung [GSF]; observation arm). The 4-, 6-, and 10-year follow-up examinations of the Munich study center were covered by the Helmholtz Zentrum Munich (former GSF), Ludwig-Maximilians-Universität Munich, and Technische Universität Munich. The LISAplus study (Munich study center) was supported by the Federal Ministry for Education, Science, Research and Technology and the Helmholtz Zentrum Munich (former GSF). The imputation for GINIplus and LISAplus was supported by the Munich Center of Health Sciences as part of the Ludwig-Maximilians University Munich LMU initiative. The CAPPS was supported by the Canadian Institutes of Health Research, the British Columbia Lung Association, and the Manitoba Medical Service Foundation. The SAGE was supported by the Canadian Institutes of Health Research. The “Traffic Asthma and Genetics” collaboration was supported by the AllerGen Networks of Centres of Excellence. E. Fuertes was supported by the AllerGen Networks of Centres of Excellence (Canadian Allergy and Immune Diseases Advanced Training Initiative) and the Canadian Institutes of Health Research (Sir Frederick Banting and Charles Best Canada Graduate Scholarship and Michael Smith Foreign Study Supplement Award). The aforementioned funding sources had no involvement in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. |
|
Disclosure of potential conflict of interest: D. S. Postma's institution has received consultancy fees from AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, TEVA, and Takeda; she has received or has grants pending from Chiesi, from which she has also received payment for delivering lectures. G. Pershagen's institution has received funding from the Swedish Research Council and the Swedish Environmental Protection Agency. M. Brauer's institution has received funding from AllerGen Networks of Centres of Excellence, as has E. Fuertes, who has also received funding from the Canadian Institutes of Health Research. G. H. Koppelman's institution has received funding from the Dutch Lung Foundation. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 135 - N° 2
P. 573 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?